This study suggests that patients with isolated type II endoleak demonstrate equivalent aneurysm-related mortality and an improved all-cause survival. A conservative approach to the treatment of type II endoleak appears to be safe.
INTRODUCTION
Endoleak may be defined as a continued perfusion of the aneurysm sac despite endograft deployment. Type II endoleak is the most common type of endoleak, the most frequent complication of endovascular abdominal aortic aneurysm repair (EVAR) occurring in approximately 10% of patients 1 and may be defined as the backflow of blood from aortic collateral arteries into the aneurysm sac. Despite this, the natural history of type II endoleak is currently unclear, with several retrospective studies suggesting it to be a benign complication 2 while others have associated type II endoleak with adverse late outcomes 3, 4 such as continued sac expansion and rupture.
Aortic aneurysm rupture after EVAR secondary to an isolated type II endoleak is rare 5 and the impact of sac expansion on risk of rupture in patients with an isolated type II endoleak is unknown. The decision to intervene is often down to surgeon preference and although vascular centres that do not routinely attempt to abolish the type II endoleak (with or without sac expansion) have reported good outcomes, 2 an optimal strategy for treatment is currently lacking. 6 The aim of this study was to examine the incidence and outcomes of type II endoleak, at a single institution that conservatively manages patients with type II endoleak.
METHODS
Within this study, 904 consecutive patients who underwent EVAR for AAA between September 1995 and July 2013 at a single centre were entered onto a prospective database. EVARs were performed by a dedicated vascular team with choice of To access continuing medical education questions on this paper, please go to www.vasculareducation.com and click on 'CME'endograft being dependent on aortoiliac morphology and operator preferences. Collected data included preoperative patient demographics, for example the presence of comorbidities (smoking, diabetes, chronic renal failure, ischaemic heart disease, hypertension, and cerebrovascular disease), preoperative aneurysm diameter, and intraoperative details.
Following EVAR, patients were followed up at regular outpatient appointments with clinical examination and duplex ultrasound scan (DUSS) at 1, 3, and 6 months postoperatively, and at 6-monthly intervals thereafter. At the time of DUSS, data were recorded on sac size, including the presence or absence of endoleak. Computed tomography (CT) scans were performed as necessary to confirm or clarify complications detected by DUSS. All outcomes including the presence of endoleak, stent migration, stent kinking, conversion to open surgical repair, rupture, and death were recorded prospectively on a research database. Those patients in whom DUSS was not possible due to large body habitus were followed up with yearly CT scans with data as above recorded.
Currently DUSSs are performed by a trained vascular technician using a GE Logiq E9 scanner (Fairfield, CA, USA) with a C1e5 MHz broadband curved array transducer (B-mode imaging, colour flow imaging and spectral Doppler modalities); however, over the study period this centre also used a Philips Medical Systems HDI 5000 duplex ultrasound scanner (Bothell WA, USA) with a C5e2 MHz broadband curved array transducer (B-mode imaging, colour flow imaging, and spectral Doppler modalities). B-mode imaging of the aneurysm sac was performed in transverse and longitudinal planes to identify the graft and to examine the sac contents. The maximum sac diameter (outer wall to outer wall) was measured in both anteroposterior and lateral planes (side-to-side diameter from the coronal position) and any changes in sac size were determined. Outer wall to outer wall diameter measurements have recently been demonstrated to have a high repeatability and reproducibility. 7 Colour flow imaging was the principal method used to examine the sac for evidence of endoleak. The colour flow scanner controls were also optimized to detect lowvelocity flow from very small endoleaks. Spectral Doppler recordings were taken from any endoleak to examine flow characteristics (pendulum flow suggesting a blind-ending endoleak, or directional flow that might suggest both inflow and outflow). Type II endoleak was defined as blood flow outside the stent graft but within the aneurysm sac caused by retrograde filling from aortic side branches.
Patients with inflammatory or infective aneurysms were excluded from this study. The primary analysis performed aimed to compare those with type II endoleak against a group with no post-EVAR complications by excluding all patients who died within 30 days of EVAR and those who developed other complications of EVAR, for example endoleak (other than type II endoleak), graft migration, and graft kinking. A subgroup analysis aimed to compare outcomes in those with type II endoleak against those without type II endoleak. The no type II endoleak group included patients who had died within 30 days of EVAR and those who had developed other complications of EVAR, for example endoleak (other than type II endoleak), graft migration, and graft kinking. Dangerous/life-threatening complications of EVAR were recognized at follow-up and treated urgently to prevent death, and all type I endoleaks detected in clinic were admitted with a view to inpatient treatment. Any type I endoleak detected on completion angiogram were treated within the first operation. The primary outcome measures were all-cause mortality, aneurysm-related mortality, and freedom from aneurysm growth. Separate analysis were performed in patients with more than 5 mm of sac expansion (compared to original sac size) and those with more than 10 mm of sac expansion (compared to original sac size). Secondary outcomes included spontaneous resolution of the endoleak, defined as no visible type II endoleak on two consecutive DUSS with no intervention having been performed.
Statistical analysis
Patients were analysed separately according to the presence or absence of a type II endoleak. Those with type II endoleak were further classified according to the nature of type II endoleak including early (first imaged on initial post EVAR DUSS), late (first imaged more than 12 months after EVAR), and persistent (present for more than 6 months). Continuous variables were expressed as mean and standard deviation (SD) or median and interquartile range (IQR) depending on the variance, and were analysed by the Fisher exact test or the ManneWhitney U test where appropriate. KaplaneMeier analysis was used to estimate all-cause mortality survival rates and freedom from aneurysm sac growth rates with log rank analysis used to test the equality of survival distributions between different factors. Censoring occurred on the last date that a patient was known to be alive or had attended an outpatient appointment if lost to follow-up. Cox proportional hazards regression was used to test for independent associations with risk of type II endoleak and sac expansion with results expressed as odds ratios (OR) and confidence intervals (CI). Stepwise selection of the following covariates was performed: age, sac diameter, ischaemic heart disease, hypertension, diabetes, cerebral vascular disease, hyperlipidaemia, chronic renal failure, current smoking, and gender. All statistical analyses were performed using SPSS v.20 (IBM Corp, Armonk, NY, USA) and assumed to be significant if p < .05.
RESULTS
During the study period, 904 consecutive patients underwent EVAR. From these 904 patients, follow-up data were available on 773 patients who were included into the analysis (data completeness 86%) from which 175 (19%) patients developed type II endoleak (Table 1) . No differences could be seen in the baseline characteristics of those patients lost to follow-up compared to those included within the analysis (Supplemental Table 1 ). Median followup was 4.1 years (1.8e6.2 years) in the no complication group and 3.6 years (1.5e5.9 years) in the type II endoleak group. No significant differences were found in preoperative demographics between the two groups. Within the group who developed type II endoleaks ( Type II endoleak rates were comparable regardless of the type of endograft used (Table 3) . Cox regression analysis adjusted for covariates (age, sac diameter, ischaemic heart disease, hypertension, diabetes, cerebral vascular disease, hyperlipidaemia, chronic renal failure, current smoking, and gender) failed to identify any significant associations with the risk of developing type II endoleak.
The association of type II endoleak with type I endoleak
Within the study period, 27 patients developed type 1 endoleak, six of whom had a type II endoleak. Three of these patients had a persistent and late type II endoleak from which two developed 10 mm of sac expansion. One patient had a persistent type II endoleak and no sac expansion, and two patients had type II endoleak with no sac size changes. Thirty-one patients had both a persistent and late type II endoleak from which only three developed a type I endoleak. These data demonstrate no association between type II endoleak and the development of a type I endoleak (p ¼ 1.0).
All-cause and aneurysm-related survival
Analysis of patients with type II endoleak versus a post EVAR, no complication group demonstrated an improved all-cause survival in patients with type II endoleak compared to those with no complication; 94.1% versus 85.6% at 3 years and 80% versus 71.4% at 5 years (p ¼ .04), a finding which persists out to 9 years; 47.7% versus 41.9% (Fig. 1) . This remained significant when including patients with known complications into the non-type II endoleak group: 94.1% versus 85.3% at 3 years, which perseveres to 9 years, 47.7% versus 40.4%; p ¼ .01.
Analysing all-cause mortality within the different classifications of type II endoleaks, those with late endoleaks appear to have a significant survival advantage compared to those with no complication (Fig. 2(A) (Fig. 2(B and C) ).
No significant difference was demonstrated between aneurysm-related mortality in the group of patients with type II endoleak compared to the group without complication: 98.1% versus 100% at 5 years and 96.8% versus 98.3 at 7 years (p ¼ .44). Eleven aneurysm ruptures occurred at a median of 41 months after discharge (IQR 9.5e52.5 months) from which two occurred in the perioperative period and nine occurred after discharge from hospital. The principle complication associated with rupture was a type 1 endoleak (n ¼ 7). One patient was reported to have a type III endoleak and consequently ruptured prior to a bridging stent being placed while another patient had a stent strut fracture. One patient who underwent elective EVAR aged 71 for a 90 mm AAA developed a persistent type II endoleak 18 months after EVAR and sac expansion (more than 10 mm from original sac size). The type II endoleak was treated conservatively and the patient was admitted with a proximal type 1 endoleak 56 months after EVAR, treated with proximal cuff. At 72 months this patient was admitted with 
Sac expansion
Freedom from sac expansion (an increase of 5 mm from preoperative sac size) was demonstrated to be significantly lower in the group of patients with type II endoleak than in the group without complication (Fig. 3) 3.3, 95% CI 1.87e4.91; p ¼ .0001) but failed to demonstrate this with sac expansion of more than 10 mm (Fig. 4 , p ¼ .1).
Reintervention after EVAR
Interventions to abolish a type II endoleak were not routinely performed after any specific time period or at any specific sac diameter change; thus, any decision to intervene was down to surgeon/patient preference. A total of nine interventions have been performed to embolize a type II endoleak. (One direct sac puncture and eight transarterial interventions.) Seven of these interventions were in patients who had more than 10 mm of sac expansion and three out of the nine interventions were clinically successful (defined as no type II endoleak present on repeat DUSS). Three patients underwent repeat reintervention: one IMA clipping, one transarterial coil, and one conversion to open surgical repair, all of which were successful. The patient who underwent conversion to open repair had a persistent type II endoleak, failed transarterial intervention and sac expansion from 51 mm to 77 mm. No post-intervention major complications occurred.
DISCUSSION
This study demonstrates that the conservative management of type II endoleak is not associated with an increase in the risk of aneurysm-related mortality, all-cause mortality, 10 mm of sac expansion, or type I endoleak. These data therefore suggest that a conservative approach to the treatment of type II endoleak is safe. Only three out of the nine interventions performed to abolish a type II endoleak were successful, which is in line with previous data suggesting a high risk of treatment failure. 5 Although no complications were noted after intervention in this study, Haulon et al. 8 reported a post-transarterial intervention, mesenteric thrombosis, whereas Uthoff and colleagues 9 reported a pulmonary embolism secondary to leaked embolent and an endograft perforation. The risk of an aggressive approach (treating all type II endoleaks or those with 5 mm of sac expansion) may therefore outweigh any benefit.
In keeping with previous findings, 10 type II endoleak was not associated with an increase in aneurysm related mortality; however, it was associated with an increased survival: 94.1% versus 85.3% p ¼ .01. This finding was most pronounced in those with late-onset type II endoleaks (those that developed after 1 year of follow-up): 97.7% versus 86%, p ¼ .004. Although these data are not the first to note this unintuitive finding, 10 no clear explanation currently exists. Previous studies 3, 4, 11 have demonstrated an association between persistent type II endoleaks and adverse outcomes; however, these data demonstrated no increase in aneurysm or all-cause mortality in this group of patients. One explanation for the improved survival demonstrated in those with type II endoleak could be differences in patient demographics. Although no differences were seen between patient comorbidities in this study, Van Marrewijk et al. 11 found current smoking and a decreased ankleebrachial index (0.87 or less) to reduce the risk of type II endoleak. El Batti 3 and colleagues similarly demonstrated that the risk of type II endoleak was reduced in active smokers (OR 0.16, CI 95% 0.04e0.71, p ¼ .01) and patients with coronary artery disease (OR 0.65, CI 95% 0.45e0.92, p ¼ .01). It is plausible that those patients with type II endoleak have less profound atherosclerosis both peripherally and centrally; however, studies to demonstrate a reduced cardiovascular risk in this group of patients would be required to investigate this.
This study confirms an association between type II endoleak and sac expansion of 5 mm, which is in keeping with previous studies 3, 4 ; however, although growth of more than 5 mm has been shown to represent an actual change in aneurysm size rather than a measurement error, 12 intervention at this point is not evidence based. Current guidelines from the European Society of Vascular Surgery 13 are that a conservative approach is appropriate for type II endoleak without sac expansion. Intervention is recommended in the presence of an increased sac diameter of 10 mm or more, with conversion to open surgery if endovascular treatment fails (level 2b). 13 This study failed to show any association between type II endoleak and sac expansion of more than 10 mm from preoperative sac size.
Within this study, 54.2% of all type II endoleaks spontaneously resolved within a median of 7 months. The number of type II endoleaks that spontaneously resolve is variable between studies; for example, one study 2 demonstrated that 48% will resolve within 4 years while another 4 suggested that 80% would resolve within 6 months. Taken together these studies suggest that given time, type II endoleak have a reasonable chance of spontaneously resolving, a view which has been confirmed by a systematic review which demonstrated that a third of all isolated type II endoleaks spontaneously resolve up to 4 years after EVAR. 5 Choice of imaging is likely to affect the reported incidence of type II endoleak. 14, 15 CT has been reported in some studies to achieve the highest sensitivity and specificity for the detection of endoleak 15 ; however, in an effort to reduce the cumulative risk of radiation exposure associated with lifelong follow-up, many vascular centres have evolved to DUSS surveillance with CT only used to confirm suspected complications. Although DUSS surveillance may be a limitation of this study, Schmieder and colleagues 16 recently demonstrated that colour duplex imaging has a higher sensitivity in detecting endoleaks requiring intervention (90% vs. 58%) and has a better diagnostic accuracy in identifying the type of endoleak than CT, which can be improved further by utilizing contrast-enhanced ultrasound. 17 Contrast-enhanced ultrasound was not utilized during any parts of this study. Gray et al. 18 demonstrated that colour duplex imaging had a sensitivity of 100% (specificity of 85%) and could replace CT as the first-line surveillance tool following EVAR as it was associated with a reduction in the cost of surveillance without any loss of imaging accuracy. A further limitation of DUSS in general is that it is operator dependent and that its sensitivity can be reduced in patients with a raised BMI. 19 Furthermore, it is possible that some type II endoleaks are misdiagnosed type I or type III endoleak.
Some studies have suggested that diameter changes after EVAR correlate poorly with volumetric changes, which may be more informative. Future follow-up may therefore include three-dimensional ultrasound imaging. This study is limited by its retrospective nature; however, all outcomes including the presence of endoleak, conversion to open surgical repair, rupture, and death were recorded prospectively. Not all patients attended follow-up (data completeness ¼ 86%); therefore, outcome data for some patients is unavailable for analysis; however, this study did include data for 773 patients. Within this study, the number of EVARs performed was heavily weighted towards the more recent years. For example in the year 2000, 23 EVARs were performed while in 2012, 98 EVARs were performed. This reflects the increasing use of EVAR with time and skews the follow-up times achieved. Although the results of this study appear to highlight an improved survival in a group of patients with type II endoleak after EVAR, this association does not suggest that type II endoleak or growth of the aneurysm after EVAR is desirable.
A limitation of type II endoleak reporting in general is the varying definitions used by authors when referring to early, late, and persistent type II endoleaks. A classification system for reporting type II endoleaks is necessary to enable standardization of reporting and comparison of results. Furthermore, a randomized clinical trial comparing conservative, selective (sac expansion more than 10 mm), and aggressive management of type II endoleak with adequate follow-up would be required to establish a gold standard treatment strategy for these patients. However, the low outcome event rates in patients with type II endoleaks may preclude funding for, and recruitment to, such a trial owing to the large sample sizes required. 20 Data such as those reported in this study should be gathered on an international database to enable robust analysis of outcomes in patients with endoleak.
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